Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Registry for Patients Taking Uptravi
NCT03278002 · View on ClinicalTrials.gov ↗
Study Summary
This is a US multi-center, prospective, real world, observational drug registry enrolling patients actively treated with Uptravi. Participating patients will be followed prospectively for a maximum of 18 months from the date of enrollment into the registry.
Conditions Studied
Study Locations (20)
Florida
- Florida Lung Asthma and Sleep Specialists — Celebration
- Broward Pulmonary and Sleep — Fort Lauderdale
- University of Florida, HSC — Gainesville
- West Pasco Pulmonary Associates — Hudson
- University of Florida-Jacksonville College of Medicine — Jacksonville
- Central Florida Pulmonary Group — Orlando
- University of South Florida — Tampa
California
- University of California San Diego — La Jolla
- University of Southern California — Los Angeles
- VA Greater Los Angeles Healthcare Center — Los Angeles
- UCSF Medical Center — San Francisco
- Santa Barbara Cottage Hospital — Santa Barbara
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA — Torrance
Arizona
- Pulmonary Associates — Phoenix
- Cardioivascular Consultants, Ltd. — Phoenix
- University of Arizona-Clinical Translational and Regenerative Medicine — Tucson
Colorado
- University of Colorado — Aurora
- National Jewish Health — Denver
- Banner Health Research Institute — Greeley
Alabama
- University of South Alabama — Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2016-11-01 |
| Est. Completion | 2021-09-21 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03278002
The ClinicalTrials.gov registry entry for NCT03278002 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 14 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03278002 reports 20 study locations spanning 5 distinct geographic areas — top geographies include Florida, California, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03278002 about?
NCT03278002 is a clinical study titled "A Registry for Patients Taking Uptravi". This is a US multi-center, prospective, real world, observational drug registry enrolling patients actively treated with Uptravi. Participating patients will be followed prospectively for a maximum of 18 months from the date of enrollment into the registry.
What is the current status of trial NCT03278002?
This trial is currently completed. The enrollment target is 800 participants. The study started on 2016-11-01. Estimated completion is 2021-09-21.
What conditions does trial NCT03278002 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT03278002?
This trial is sponsored by Actelion, which has 14 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03278002 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.